Table 3.

Patients with SD for ≥ 24 weeks or PR by RECIST v1.1.

	Patient characteristics				Tinengotinib		Best response by RECIST version 1.1
	Cancer type	FGFR alterationsa	Prior systemic therapies, n	Previous targeted therapies	Dose, mg/day	Duration of treatment, weeks
1001-25	Cholangiocarcinoma	FGFR2 N549K, FGFR2-KCNH7 fusion	3	Derazantinib	8	38.3	PR
1001-37	Cholangiocarcinoma	FGFR2 C382R	3	Derazantinib	10	32.8	PR
1001-41b	HR+/HER2− breast cancer	FGFR2 rearrangement	13	Palbociclib; SYK/FLT3 inhibitord; PIM kinase inhibitord	12	12.1	PR
2001-50	HR+/HER2− breast cancer	None	6	None	10	25	PR
1001-74b	TNBC	None	8	None	12	16.1	PR
1001-64b	Prostate adenocarcinoma	FGFR2 amplification	13	SUMO-activating enzyme inhibitord	12	21.9	PR
1001-79b	Cholangiocarcinoma	FGFR2-CCDC6.F17C2c	4	Pemigatinib	12	28	PR
1001-34	Cholangiocarcinoma	FGFR2-AHCYL1.F17A2	4	Infigratinib	10	33.9	SD
1001-15	HR+/HER2− breast cancer	None	7	NO synthase inhibitord	8	26.1	SD
2001-24	TNBC	None	3	None	5	24.6	SD
1001-66b	Rectum adenocarcinoma	FGFR1 amplification	5	Pemigatinib	12	26	SD
1001-67b	Epithelioid mesothelioma	None	3	Bevacizumab	12	50.4	SD
1001-05	Salivary gland adenocarcinoma	None	3	Ceritinib; abemaciclib	5	36.4	SD

Abbreviations: DRDE, dose recommended for dose expansion; FGFR, fibroblast growth factor receptor; FLT3, FMS-like tyrosine kinase 3; HER2−, human epidermal growth factor 2-negative; HR+, hormone receptor-positive; NO, nitric oxide; PIM, proviral integration site of Moloney murine leukemia virus; PR, partial response; RECIST, Response Evaluation Criteria in Solid Tumors; SD, stable disease; SUMO, small ubiquitin-like modifier; SYK, spleen tyrosine kinase; TNBC, triple-negative breast cancer.

^aIndicates historical FGFR mutational status obtained from medical records review.

^bIndicates patient treated at DRDE.

^cIndicates FGFR mutational status obtained from next-generation sequencing performed during study screening and prior to study entry.

^dInvestigational agent under study.